Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 5/20 | 0.37 |
| ▸ | EDNRA | P25101 | 4/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292776 | 0.92 | LMNA (0.37) | LMNAGAAEDNRBEDNRAPIK3CD | |
| SCHEMBL6289260 | 0.89 | EDNRA (0.40) | EDNRBEDNRAPIK3CD | |
| SCHEMBL6293113 | 0.89 | LMNA (0.34) | LMNAGAAEDNRBEDNRAPIK3CD | |
| SCHEMBL6289272 | 0.89 | PIK3CD (0.35) | LMNAGAAEDNRBEDNRAPIK3CD | |
| SCHEMBL6292702 | 0.86 | FYN (0.34) | LMNAGAAEDNRBFYNPIK3CD | |
| SCHEMBL6289312 | 0.85 | EDNRA (0.40) | EDNRBEDNRA | |
| SCHEMBL6289621 | 0.79 | EDNRA (0.48) | EDNRBEDNRA | |
| SCHEMBL6289631 | 0.78 | EDNRA (0.41) | EDNRBEDNRAPIK3CDMAPT | |
| SCHEMBL6289638 | 0.78 | MAPT (0.44) | EDNRBEDNRAPIK3CDMAPT | |
| SCHEMBL6289757 | 0.77 | GAA (0.38) | LMNAGAAEDNRBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6610518-B2 | Using Cytochrome p450 | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| US-20020012977-A1 | Enzymatic oxidations | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1160331-A1 | Enzymatic oxidations | Pfizer Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | LMNA 2329/4885GAA 4770/4885EDNRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.